A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Inclusion Criteria

• Participants must have histologic documentation of advanced recurrent or metastatic cancer.
• Participants must be at the recurrent/metastatic setting, with selected advanced solid tumors.
• Participants must have at least one lesion that is measurable by RECIST v1.1
• Part 3, Dose exploration, CRC participants can be treatment naïve but should not have received more than two line of systemic therapy in the recurrent/metastatic setting.

Exclusion Criteria

• Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor.
• Prior participation in clinical studies that include durvalumab alone or in combination, where the study has registrational intent and the analyses for the primary endpoint have not yet been completed
• Receipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of study treatment
• Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.